Axel F. Grothey
Expertise in
6
conditions

Dr. Axel F. Grothey

The West Clinic, PLLC
Brighton, TN
Expertise in
6
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
OverviewInsuranceLocationsClinical Research

Overview

Axel Grothey is a Hematologist Oncology specialist and an Oncologist in Brighton, Tennessee. Dr. Grothey is highly rated in 6 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Febrile Neutropenia, Agranulocytosis, Hepato-Pancreato-Biliary Surgery, and Hepatectomy. Dr. Grothey is currently accepting new patients.

His clinical research consists of co-authoring 269 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TN
Hospital Affiliations
Regional One Health
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

THE WEST CLINIC, PLLC
240 Grandview Dr, Brighton, TN 38011
901-475-0678
Other Locations
THE WEST CLINIC, PLLC
7945 Wolf River Blvd, Germantown, TN 38138
901-683-0055
THE WEST CLINIC, PLLC
1588 Union Ave, Memphis, TN 38104
901-300-1562

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Other, Drug
Study Drugs: Clobetasol propionate, Regorafenib
Study Phase: Phase 2
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

270 Total Publications

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: June 18, 2024
Similar Doctors
Raymond U. Osarogiagbon
Expertise in
12
conditions
Dr. Raymond U. Osarogiagbon
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Raymond U. Osarogiagbon
Hematology Oncology | Hematology | Oncology

Baptist Memorial Hospital-Tipton

6029 Walnut Grove Rd, Suite 301, 
Memphis, TN 
 (24.5 mi)
901-747-9087
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raymond Osarogiagbon is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Osarogiagbon is highly rated in 12 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Lung Adenocarcinoma, and Endoscopy. Dr. Osarogiagbon is currently accepting new patients.

Expertise in
9
conditions
Dr. Kenneth I. Ataga
Hematology Oncology | Hematology | Oncology
Expertise in
9
conditions
Dr. Kenneth I. Ataga
Hematology Oncology | Hematology | Oncology

UT Regional One Physicians Inc

890 Madison Ave, 
Memphis, TN 
 (28.0 mi)
901-545-8999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Ataga is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Ataga is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Ataga is currently accepting new patients.

Expertise in
65
conditions
Dr. Michael G. Martin
Hematology Oncology | Oncology | Hematology
Expertise in
65
conditions
Dr. Michael G. Martin
Hematology Oncology | Oncology | Hematology

The West Clinic, PLLC

240 Grandview Dr, 
Brighton, TN 
901-475-0678
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Martin is a Hematologist Oncology specialist and an Oncologist in Brighton, Tennessee. Dr. Martin is highly rated in 65 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Martin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile